Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Net (2021 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Receivables - Net data on record, last reported at $85.1 million in Q4 2025.

  • For Q4 2025, Receivables - Net rose 81.9% year-over-year to $85.1 million; the TTM value through Dec 2025 reached $85.1 million, up 81.9%, while the annual FY2025 figure was $85.1 million, 81.9% up from the prior year.
  • Receivables - Net reached $85.1 million in Q4 2025 per TARS's latest filing, up from $72.6 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $85.1 million in Q4 2025 and bottomed at $17000.0 in Q1 2022.
  • Average Receivables - Net over 5 years is $30.2 million, with a median of $27.1 million recorded in 2021.
  • Peak YoY movement for Receivables - Net: tumbled 99.93% in 2022, then surged 31441.18% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $20.0 million in 2021, then plummeted by 99.92% to $17000.0 in 2022, then skyrocketed by 97670.59% to $16.6 million in 2023, then surged by 181.33% to $46.8 million in 2024, then surged by 81.9% to $85.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $85.1 million in Q4 2025, $72.6 million in Q3 2025, and $58.3 million in Q2 2025.